Latest medical advances on biomarkers in the diagnosis and follow-up of lung neoplasms
DOI:
https://doi.org/10.52076/eacad-v3i3.305Keywords:
Lung neoplasms; Biomarkers; Diagnosis.Abstract
Lung cancer is one of the most common neoplasms today, with a high mortality rate for this type of neoplasm that has been increasing, in part due to aging, population growth, changes in the distribution and prevalence of cancer risk factors, especially associated with socioeconomic development. These biomarkers are tools that can be useful in the clinical management of patients with lung cancer detected at an early stage, helping in the processes of diagnosis of malignancy, staging, evaluation of therapeutic response, detection of recurrences and prognosis, in the development of new treatment modalities preventing a response to adjunctive therapy for cases at high risk of relapse. Thus, the present review proposes to analyze and unravel the possible biomarkers found in lung cancers and influence and help in the diagnosis and prognosis of lung cancer. The present study is a systematic, interactive and qualitative review, evaluating publications from 2017 to 2022. A survey was carried out in the PubMed database, and the association of these markers with lung cancer could be seen, being It is possible to use these in the early diagnosis and in the assessment of the prognosis of patients.
References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
Chen, R.L., Zhao, J., Zhang, X.C., Lou, N.N., Chen, H.J., Yang, X., Su, J., Xie, Z., Zhou, Q., Tu, H.Y., Zhong, W.Z., Yan, H.H., Guo, W.B., Wu, Y.L., Yang, J. J. (2018). Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. BMC Cancer. Nov 26;18(1):1171. https://doi.org/10.1186/s12885-018-5078-y
Chu, G. C., Lazare, K., & Sullivan, F. (2018). Serumandbloodbasedbiomarkers for lungcancerscreening: a systematic review. BMC cancer, 18(1), 1-6. https://doi.org/10.1186/s12885-018-4024-3.
Evans M. (2013). Lung cancer: needs assessment, treatment and therapies. British journal of nursing (Mark Allen Publishing), 22(17), S15–S22. https://doi.org/10.12968/bjon.2013.22.Sup17.S15
Didkowska, J. et al. Lung cancer epidemiology: contemporary and future challenges worldwide. Annals of Translational Medicine, 4(8), 1-11, https://doi.org/10.21037/atm.2016.03.11
Fan, K., Zhang, C. L., Qi, Y. F., Dai, X., Birling, Y., Tan, Z. F., & Cao, F. (2020). PrognosticValueof EZH2 in Non-Small-Cell Lung Cancers: A Meta-AnalysisandBioinformaticsAnalysis. BioMed Research International, 2020, 2380124. https://doi.org/10.1155/2020/2380124
He, J., Huang, Z., Han, L., Gong, Y., Xie, C. (2021). Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). International Journal of Oncology. Nov; 59(5),1-20.https://doi.org/10.3892/ijo.2021.5270
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A., & Cronin, K. A. (2014). US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI: Journal of the National Cancer Institute, 106(5). https://doi.org/10.1093/jnci/dju055
Jian, W., Ming-Ya, P., Long-Bao, X., Jun, Z., &Guo-Qiang, S. (2020). Correlation between Skip N2 Metastases and SUVmax, LongDiameter of Tumor, and Ki67 Expression in Patients with Non-Small-Cell Lung Cancer. BioMed research international, 2020, 9298358. https://doi.org/10.1155/2020/9298358
Jiang, Y. M., Yu, D. L., Hou, G. X., Jiang, J. L., Zhou, Q., & Xu, X. F. (2019). Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer. Bioscience Reports, 39(7), BSR20190476. https://doi.org/10.1042/BSR20190476
Lan, B., Wang, Y., Wu, J., Wang, K., & Wang, P. (2021). The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis. Medicine, 100(34), e27038. https://doi.org/10.1097/MD.0000000000027038
Li, J., Wang, Y., Li, J., & Che, G. (2021). Prognostic Value of Pretreatment D-DimerLevel in Small-CellLungCancer: A Meta-Analysis. Technology in cancer research treatment, 20, 1533033821989822. https://doi.org/10.1177/1533033821989822
Li, J., Shen, C., Wang, X., Lai, Y., Zhou, K., Li, P., Liu, L., & Che, G. (2019). Prognostic value of TGF-β in lung cancer: systematic review and meta-analysis. BMC cancer, 19(1), 691. https://doi.org/10.1186/s12885-019-5917-5
Li, X., Mao, W., Guo, D., & Xu, H. (2019). ClinicopathologicalSignificanceandDiagnosticValueof DLEC1 Hypermethylation in Lung Cancer: A Meta-analysis. Journal of Nippon Medical School, 86(2), 62–69. https://doi.org/10.1272/jnms.JNMS.2019_86-201
Lin, C., Lin, X., Lin, K., Tan, J., Wei, C., & Liu, T. (2021). LKB1 expression and the prognosis of lung cancer: A meta-analysis. Medicine, 100(46), e27841. https://doi.org/10.1097/MD.0000000000027841
Liu, F., Lu, X., Zhou, X., & Huang, H. (2021). APC gene promoter methylation as a potential biomarker for lung cancer diagnosis: A meta-analysis. Thoracic Cancer, 12(21), 2907–2913. https://doi.org/10.1111/1759-7714.14151
Mazieres, J., Cropet, C., Montané, L., Barlesi, F., Souquet, P. J., Quantin, X., ... & Blay, J. Y. (2020). Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Annals of Oncology, 31(2), 289-294.https://doi.org/10.1016/j.annonc.2019.10.022
Miao, T. W., Xiao, W., Du, L. Y., Mao, B., Huang, W., Chen, X. M., Li, C., Wang, Y., & Fu, J. J. (2021). High expression of SPP1 in patients with chronic obstructive pulmonary disease (COPD) is correlated with increased risk of lung cancer. FEBS open bio, 11(4), 1237–1249. https://doi.org/10.1002/2211-5463.13127
Min, S. H., & Zheng, Q. Q. (2021). Clinicopathological and prognostic significance of NM23 expression in patients with non-small cell lung cancer: A systematic review and meta-analysis. Medicine, 100(47), e27919. https://doi.org/10.1097/MD.0000000000027919
Muley, T., He, Y., Rolny, V., Wehnl, B., Escherich, A., Warth, A., ... & Dayyani, F. (2019). Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung. Lung Cancer, 130, 194-200. https://doi.org/10.1016/
Nielsen, J. B. (2008). Metabolomics. Topics in Current Genetics. Springer Verlag, Heidelberg, 18.https://doi.org/10.1007/4735_2007_0228
Pan, J., Bian, Y., Cao, Z., Lei, L., Pan, J., Huang, J., Cai, X., Lan, X., & Zheng, H. (2020). Long noncoding RNA MALAT1 as a candidate serological biomarker for the diagnosis of non-small cell lung cancer: A meta-analysis. Thoracic cancer, 11(2), 329–335. https://doi.org/10.1111/1759-7714.13265
Pandit-Taskar, N., Postow, M. A., Hellmann, M. D., Harding, J. J., Barker, C. A., O’Donoghue, J. A., ... & Wolchok, J. D. (2020). First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. Journal of Nuclear Medicine, 61(4), 512-519. https://doi.org/10.2967/jnumed.119.229781
Qi, S. A., Wu, Q., Chen, Z., Zhang, W., Zhou, Y., Mao, K., ... & Huang, Y. (2021). High-resolution metabolomic biomarkers for lung cancer diagnosis and prognosis. Scientific Reports, 11(1), 1-10. https://doi.org/10.1038/s41598-021-91276-2
Seijo, L. M., Peled, N., Ajona, D., Boeri, M., Field, J. K., Sozzi, G., ... & Montuenga, L. M. (2019). Biomarkers in lung cancer screening: achievements, promises, and challenges. Journal of Thoracic Oncology, 14(3), 343-357. https://doi.org/10.1016/j.jtho.2018.11.023
Sun, N., Sun, S., Gao, Y., Li, Y., Lu, Z., Yuan, Z., Che, Y., Huang, J., Mao, S., Lei, Y., Zang, R., Li, N., Cui, W., Qi, J., Chen, F., Gao, J., Wang, J., Min, R., Chen, Y., Shi, G., … He, J. (2020). Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non-small-cell lung cancer: A multicenter in vitro diagnostic clinical trial. Cancer Science, 111(5), 1739–1749. https://doi.org/10.1111/cas.14387
Tang, Z. M., Ling, Z. G., Wang, C. M., Wu, Y. B., & Kong, J. L. (2017). Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis. PloS One, 12(7), e0182117. https://doi.org/10.1371/journal.pone.0182117
Timar, J., & Kashofer, K. (2020). Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer and Metastasis Reviews, 39(4), 1029-1038. https://doi.org/10.1007/s10555-020-09915-5
Tong, M., Wang, J., Jiang, N., Pan, H., & Li, D. (2017). Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis. PloS One, 12(8), e0182282. https://doi.org/10.1371/journal.pone.0182282
Torre, L.A., Siegel, R.L., Ward, E.M.. (2015). Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiology Biomarkers & Prevention, v. 25, n. 1, p. 16. https://doi.org/10.1158/1055-9965.EPI-15-0578
Tuo, L., Sha, S., Huayu, Z., & Du, K. (2018). P16INK4a gene promoter methylation as a biomarker for thediagnosisof non-small cell lung cancer: An updated meta-analysis. Thoracic cancer, 9(8), 1032–1040. https://doi.org/10.1111/1759-7714.12783
Wadowska, K., Bil-Lula, I., Trembecki, Ł., & Śliwińska-Mossoń, M. (2020). Genetic markers in lung cancer diagnosis: A review. International journal of molecular sciences, 21(13), 4569. https://doi.org/10.3390/ijms21134569
Wang, B., Tang, Y. D., Yu, B., Gui, D., & Xu, H. (2019). Expression of autophagy-related factor p62 for lung cancer diagnosis and prognosis: A systematic review and meta-analysis. Mathematical Biosciences and Engineering, 16(6), 6805-6821. https://doi.org/10.3934/mbe.2019340
Wang, J.F., Wang, Y.P., Xie, J., Zhao, Z.Z., Gupta, S., Guo, Y., Jia, S.H., Parodo, J., Marshall, J.C., Deng, X.M. (2021) Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis. Blood. Sep 2; 138(9): 806-810. https://doi.org/10.1182/blood.2020009417.
Winther-Larsen, A., Aggerholm-Pedersen, N., & Sandfeld-Paulsen, B. (2021). Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis. Systematic reviews, 10(1), 40. https://doi.org/10.1186/s13643-021-01585-w
World Health Organization. Who report on cancer: setting priorities, investing wisely and providing care for all. Geneva: WHO, 2020. https://apps.who.int/ iris/handle/10665/330745. Acesso em: 18 set. 2022.
World Health Organization. Guide to cancer early diagnosis. Geneva: WHO, 2017. https://apps.who.int/iris/bitstream/handle/10665/254500/9789241511940-eng. pdf?sequence=1. Acesso em: 18 set. 2022.
Yu, M.D.L., Hou, G.X., Jiang, J.L., Zhou, Q., Xu, X. F. (2019). Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer. Bioscience Reports, 39(7), BSR20190476. https://doi.org/10.1042/BSR20190476
Yuan, Y., Xu, X. Y., Zheng, H. G., & Hua, B. J. (2018). Elevated miR-21 is associated with poor prognosis in non-small cell lung cancer: a systematic review and meta-analysis. Eur. Rev. Med.l Pharmacol. Sci, 22(13), 4166–4180. https://doi.org/10.26355/eurrev_201807_15410
Xu, C.M., Luo, Y.L., Li, S., Li, Z.X., Jiang, L., Zhang, G.X., Owusu. L., Chen, H.L. (2019), Multifunctional neuron-specific enolase: its role in lung diseases. Bioscience Reports. Nov 29;39(11):BSR20192732. https://doi.org/10.1042/BSR20192732
Zang, R., Wang, X., Jin, R., Lei, Y., Huang, J., Liu, C., Zheng, S., Zhou, F., Wu, Q., Sun, N., Gao, S., & He, J. (2019). Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity. Journal of translational medicine, 17(1), 430. https://doi.org/10.1186/s12967-019-2117-7
Zhang, M., Li, G., Wang, Y., Wang, Y., Zhao, S., Haihong, P., Zhao, H., & Wang, Y. (2017). PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Scientific Reports, 7(1), 10255. https://doi.org/10.1038/s41598-017-10925-7
Zhou, X., Lu, X., Wu, H., Liu, J., & Huang, H. (2021). Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta-analysis update. Thoracic cancer, 12(24), 3327–3332. https://doi.org/10.1111/1759-7714.14206
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Mariana Acioly Cavalcanti de Albuquerque; Matheus Acioly Cavalcanti de Albuquerque; Marina Acioly Cavalcanti de Albuquerque; Vinicius José Paulino Vergetti; Jordy Silva de Carvalho; Arlene de Siqueira Mendes Costa; Luiz Américo do Lago Silva; Klaus de Morais Freire; Nathália Vieira de Souza Eugênio; Ruth Elen Gonçalves Sales da Silva Santos; Vitor Mateus Rocha Bernardes; Bereneuza Tavares Ramos Valente Brasileiro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
